(NASDAQ: FLGT) Fulgent Genetics's forecast annual revenue growth rate of 9.62% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.26%.
Fulgent Genetics's revenue in 2026 is $323,932,000.On average, 3 Wall Street analysts forecast FLGT's revenue for 2026 to be $9,309,249,081, with the lowest FLGT revenue forecast at $8,944,396,296, and the highest FLGT revenue forecast at $9,583,301,399. On average, 3 Wall Street analysts forecast FLGT's revenue for 2027 to be $10,740,594,623, with the lowest FLGT revenue forecast at $10,319,610,640, and the highest FLGT revenue forecast at $11,056,745,339.
In 2028, FLGT is forecast to generate $12,086,642,756 in revenue, with the lowest revenue forecast at $11,330,797,657 and the highest revenue forecast at $12,744,533,412.